Topic 126

cancer tumor therapy treatment tumors inhibitors therapeutic efficacy resistance anti combination inhibitor targeting patients biology chemotherapy therapies survival drug clinical vivo patient cancers inhibition cells preclinical effective immunotherapy drugs resistant targeted blockade cell glioblastoma checkpoint vitro models agents glioma response growth lines xenografts breast immune pd xenograft approved bearing myeloid aggressive trials ovarian microenvironment treated derived treatments radiation care expression primary metastatic agent standard strategy sensitivity alone gbm leukemia promising cytotoxic induced benefit sensitive mice antitumor clinically viability solid target radiotherapy synergistic pdx combined chemotherapeutic poor signaling increased malignancies antibody kinase l1 parp temozolomide car apoptosis upregulation murine toxicity syngeneic

231 items. Top items listed below.

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 126 14 10 3

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 126 14 10 9

Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance 126 14 10 3

PD-L1 lncRNA splice promotes lung adenocarcinoma progression via enhancing c-Myc activity 108 14 10 3

Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment 173 126 14 10 3

ATM Inhibition Synergizes with Fenofibrate in High Grade Serous Ovarian Cancer Cells 126 14 10 9 3

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways 138 126 14 10 3

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors 138 126 14 10 3

225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models 126 14 10 3

Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma 126 14 10 3

Gamma secretase inhibitors inhibit ovarian cancer development and enhance olaparib's anti-ovarian cancer activity and its mechanism 126 108 14 10 3

Taxane induces attenuation of the CXCR2/BCL-2 axis and sensitize prostate cancer to platinum-based treatments 126 14 10 3

AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells 126 14 10 3

Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal Tumors 152 126 14 10 3

Restructuring of the Immune Contexture Improves Checkpoint Blockade Efficacy in Murine Lung Cancer 126 14 10

Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer 98 14 10 3

Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model 126 14 10 9 3

The Dopamine Receptor Antagonist TFP Prevents Phenotype Conversion and Improves Survival in Mouse Models of Glioblastoma 126 14 10 3

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers 138 126 14 10 3

SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors 126 14 10 3

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis 126 108 14 10 3

Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome 126 14 10

Combined Treatment with Dopamine Receptor Antagonists and Radiation Creates a Metabolic Vulnerability in Mouse Models of Glioblastoma 126 14 10 3

IL-4 receptor targeting as an effective immunotherapy against triple-negative breast cancer 126 14 10 3

Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer 126 108 14 10 3

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach 126 14 10 3

Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. 126 14 10 3

FLASH irradiation enhances the therapeutic index of abdominal radiotherapy for the treatment of ovarian cancer 126 14 10 3

A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer 152 126 14 10 3

Dual blockade of IL-6 and CTLA-4 regresses pancreatic tumors in a CD4+ T cell-dependent manner. 126 14 10 3

A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors 126 14 10 3

MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer. 126 108 14 10 3

Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer. 126 14 10 3

Modulation of Early Mitotic Inhibitor 1 (EMI1) Depletion on the Sensitivity of PARP Inhibitors in BRCA1 Mutated Triple-Negative Breast Cancer Cells 138 126 14 10 3

PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages 126 14 10 3

Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma 138 126 46 7 3

Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer 126 14 10 3

Chemotherapy but not the tumor-draining lymph nodes determine the immunotherapy response in secondary tumors 126 14 10 3

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma 126 14 10 3

Loss of Caspase-8 function in combination with SMAC mimetic treatment sensitizes Head and Neck Squamous Carcinoma to radiation through induction of necroptosis 126 108 14 10 3

HDAC and MAPK/ERK inhibitors cooperate to reduce viability and stemness phenotype in medulloblastoma 186 108 14 10 3

Beta 1 Integrin Signaling Mediates Pancreatic Ductal Adenocarcinoma Resistance to MEK Inhibition 126 108 14 10 3

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Ka/b/δ and anti-PD-1 treatment 126 14 10 3

Repurposing the antidepressant sertraline as SHMT inhibitor to suppress serine/glycine synthesis addicted breast tumor growth. 126 14 10 3

Changes in the tumor microenvironment and treatment outcome in glioblastoma: A pilot study 126 14 10 3

Vulnerability of ARID1A deficient cancer cells to pyrimidine synthesis blockade 126 14 10 3

HIF1α inhibition by dual targeting of CDK4/6 and HSP90 reduces cancer cell viability including Rb-deficient cells 126 108 14 10 3

Inhibition of p-glycoprotein does not increase the efficacy of proteasome inhibitors in multiple myeloma cells 126 14 10 3

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells 126 88 14 10 3

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells 126 14 10 3

Inhibition of the av integrin-TGF-b axis improves natural killer cell function against glioblastoma stem cells 152 14 10 3

Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy 126 14 10 3

RIPK2 Stabilizes c-Myc and is an Actionable Target for Inhibiting Prostate Cancer Metastasis 108 14 10 3

A single cell atlas reveals distinct immune landscapes in transplant and primary tumors that determine response or resistance to immunotherapy 126 14 10 3

Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies 126 14 10 3

TNFRSF14 (HVEM) is a novel immune checkpoint blockade that can be targeted by a monoclonal antibody to improve anti-tumor immunity in humanized mice 126 14 10 3

The irradiated brain microenvironment supports glioma stemness and survival via astrocyte-derived Transglutaminase 2 126 14 10 3

Selective Vulnerability of Senescent Glioblastoma Cells to Bcl-XL Inhibition 126 14 10 3

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma 126 14 10 3

A computational network approach to identify predictive biomarkers and therapeutic combinations for anti-PD-1 immunotherapy in cancer 126 112 14 9

LNX1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem Cell Population During Temozolomide Therapy in Glioblastoma 186 126 14 10 3

Cell-line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations 126 14 10

Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors 138 126 14 10 3

The Injury Response to DNA Damage Promotes Anti-Tumor Immunity 126 88 10 3

LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency 126 14 10 3

Divergent resistance mechanisms to immunotherapy explains response in different skin cancers. 173 14 10 3

Inducible transgene expression in PDX models in vivo identifies KLF4 as therapeutic target for B-ALL 152 126 14 10 3

Individual cell-based modeling of tumor cell plasticity-induced immune escape after CAR-T therapy 126 14 10 3

ATR inhibition enhances 5-fluorouracil sensitivity independent of non-homologous end-joining and homologous recombination repair pathway 46 14 10 3

Identification of clinical combination therapies to induce durable responses in kidney cancers 126 14 10 3

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells 108 14 10 3

A novel mechanism of natural killer cell response to anti-CTLA-4 therapy identified by integrative analysis of mouse and human tumors 14 10 9 3

Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T cell Mediated Anti-Tumor Response and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression 126 14 10 3

Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling 108 14 3

Patient-tailored design of AML cell subpopulation-selective drug combinations 112 14 4

A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin 126 108 14 10 3

Specific Inhibition of GSK-3β by Tideglusib: Potential Therapeutic Target for Neuroblastoma Cancer Stem Cells 126 108 14 10 3

Inhibition of USP28 overcomes Cisplatin-Resistance of Squamous Tumors by Suppression of the Fanconi Anemia Pathway. 126 14 3

Modelling CAR T-cell Therapy with Patient Preconditioning 126 14 10

Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity 126 14 10 3

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor 7 3

Ivermectin converts cold tumors hot and synergies with immune checkpoint blockade for treatment of breast cancer 126 14 10 3

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells 152 126 14 10 3

Regulation of lipid accumulation-induced ROS in myeloid-derived suppressor cells via targeting fatty-acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy 126 108 14 10 3

Topsentinol L Trisulfate, a new Marine Natural Product, that Targets Basal-like and Claudin-low Breast Cancers 126 14 10 9 3

Response to CAR T cell therapy can be explained by ecological cell dynamics and stochastic extinction events 14 10

Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells 126 14 10 3

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma 126 14 10 3

ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells 108 14 3

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit 108 14 10 3

Targeting the Src pathway enhances the efficacy of selective FGFR inhibitors in cancers with FGFR3 alterations 126 14 10 3

Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemia 126 14 10 9 3

Integrated genomics and comprehensive validation reveal novel drivers of genomic evolution in esophageal adenocarcinoma 14 9 3

Pharmacologically modified pluripotent stem cell-based cancer vaccines with anti-metastatic potential 126 14 10 3

Sustained Androgen Receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis 108 14 10 3

Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance 152 126 14 10 3

BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer 108 14 10 3

MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma 138 126 14 10 3

Targeting hypoxic habitats with hypoxia pro-drug evofosfamide in preclinical models of sarcoma 126 14 10

Potentiating the anti-tumor response of tumor infiltrated T cells by NAD+ supplementation 126 14 10 3